Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drug Development
Transdermal estradiol gel significantly decreases hot flashes in menopausal women
October 27th, 2005
BioSante Pharmaceuticals, Inc., (BPA), the North American licensee of Antares Pharma, Inc., (AIS) announced results of its phase III clinical study data on Bio-E-Gel (bio-identical estradiol gel) at the North American Menopause Society (NAMS) annual meeting in San Diego, California. The study results showed three doses of Bio-E-Gel that significantly decrease the number of hot flashes in menopausal women and identified the lowest effective dose in order to implement estrogen therapy. The phase III trial was a 12-week, randomized, double-blind, placebo- controlled study of 484 symptomatic menopausal women using three dosage levels of Bio-E-Gel in...
Source: Women's Health Weekly (2005-10-27)
|
